**London**: Ori Biotech has unveiled its Preferred Partner Network (PPN) to enhance cooperation between academic centres and manufacturing organisations, aiming to accelerate cell and gene therapy development by integrating advanced technologies and expertise to deliver crucial therapies faster to patients.
Ori Biotech has officially launched its Preferred Partner Network (PPN), a strategic initiative aimed at accelerating the development and commercialisation of cell and gene therapies. The PPN aims to enhance collaboration between academic medical centres (AMCs) and contract development and manufacturing organisations (CDMOs) to provide advanced solutions within the biopharmaceutical sector.
Notable founding members of the PPN in the United States include Charles River Laboratories, CTMC—which is a collaboration between MD Anderson Cancer Center and Resilience—ElevateBio, Kincell, along with other partners that have yet to be disclosed.
Jason C. Foster, CEO of Ori Biotech, commented on the initiative, stating, “By partnering with the top academic institutions and CDMOs globally, Ori is helping to deliver proven solutions that speed time to clinic, reduce comparability risk, and shorten development timelines.” Foster highlighted that PPN membership allows for the development of specialised expertise with Ori’s new IRO® platform, which aims to streamline cell therapy product development.
The IRO platform is designed to integrate seamlessly with various leading upstream and downstream technologies, thereby facilitating a streamlined workflow that is essential for achieving both clinical and commercial success. Foster also noted that recent technology partnerships, including collaborations with Fresenius Kabi, represent significant progress in Ori’s mission to enhance patient access to crucial cell and gene therapies.
Various representatives from PPN founding members reiterated the importance of the initiative. Matthew Hewitt, PhD, Vice President and CTO of the manufacturing business division at Charles River, expressed alignment with Ori’s objectives, stating, “Ori’s mission mirrors our own: expedite the delivery of life-saving therapies to patients.”
Jason Bock, CEO of CTMC, elaborated on the benefits of integrating Ori’s IRO platform, saying, “CTMC provides comprehensive solutions to our academic and biotech partners, enabling seamless translation from concept to clinic.” Bock indicated that the automated capabilities of the IRO platform would enhance their technology offerings, facilitating quicker delivery of cell therapies to patients.
Michael Paglia, CTO of ElevateBio BaseCamp, remarked, “Through the Ori Preferred Partner Network, we are able to offer our partners the necessary technologies and service solutions to accelerate development, manufacturing, and their path to commercialization.”
Bruce Thompson, PhD, CTO of Kincell Bio, highlighted the innovative potential of the partnership, stating, “As the cell therapy field matures, innovative technologies that simplify the manufacturing of these complex therapies and reduce the cost of goods will enable broad distribution of these life-saving medicines.” Thompson expressed enthusiasm for Kincell Bio’s collaboration with Ori Biotech on the IRO platform, emphasising its role in ensuring that cell therapy products reach those in need.
The formation of the Ori Preferred Partner Network marks a strategic move within the biopharmaceutical industry towards enhancing collaboration amongst leading entities, ultimately aiming to expedite the availability of advanced therapies to patients.
Source: Noah Wire Services
Subscribe to Industry Updates
